Literature DB >> 9824259

Serum levels of soluble Fas antigen in chronic hepatitis C patients.

S Iio1, N Hayashi, E Mita, K Ueda, K Mochizuki, N Hiramatsu, T Kanto, Y Sasaki, A Kasahara, M Hori.   

Abstract

BACKGROUND/AIMS: In chronic hepatitis C, the expression of Fas antigen on hepatocytes is upregulated and Fas ligand expression is detected on liver-infiltrating mononuclear cells. Thus Fas antigen/Fas ligand-mediated apoptosis is thought to be involved in hepatic injury in chronic hepatitis C. The soluble form of Fas antigen has been detected in serum and shown to inhibit Fas-mediated apoptosis. The present study was done to evaluate the relationship of serum soluble Fas antigen levels with disease activity.
METHODS: Serum soluble Fas antigen levels were measured by enzyme-linked immunosorbent assay for 68 chronic hepatitis C patients and compared with those in normal volunteers, chronic hepatitis B patients and autoimmune hepatitis patients. These levels were compared with histological activity, ALT levels, HCV-RNA titer and Fas expression on hepatocytes.
RESULTS: Serum soluble Fas antigen levels in chronic hepatitis C patients (3.24+/-1.55 ng/ml) were significantly higher than those in normal volunteers (1.70+/-1.01 ng/ml) (p<0.01). They showed no difference from those in chronic hepatitis B or autoimmune hepatitis patients. Histologically, soluble Fas antigen levels showed correlation with the levels of liver inflammation (p<0.01). However, no relationship was observed between serum soluble Fas antigen and serum ALT levels or HCV-RNA titer. Serum soluble Fas antigen levels showed correlation with the levels of Fas antigen expression in liver tissue (p<0.05).
CONCLUSIONS: These findings suggest that serum soluble Fas antigen may reflect the expression levels of Fas antigen on hepatocytes and the severity of liver inflammation in chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824259     DOI: 10.1016/s0168-8278(98)80145-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Correlation of CD95 and soluble CD95 expression with acute rejection status of liver transplantation.

Authors:  Yu-Liang Wang; Yan-Yan Zhang; Guang Li; Zhi-Qin Tang; Yan-Li Zhou; Zhi-Jun Zhu; Zhi Yao
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

2.  Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression.

Authors:  Nicholas A Shackel; Peter H McGuinness; Catherine A Abbott; Mark D Gorrell; Geoffrey W McCaughan
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

3.  Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Authors:  Christina M Martin; Jeffrey A Welge; Norah J Shire; Mohamed T Shata; Kenneth E Sherman; Jason T Blackard
Journal:  Cytokine       Date:  2009-07-21       Impact factor: 3.861

Review 4.  Immune cell-mediated liver injury.

Authors:  Nadia Corazza; Anastasia Badmann; Christoph Lauer
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

Review 5.  Underlying pathophysiology of HCV infection in HIV-positive drug users.

Authors:  Anuradha Balasubramanian; Jerome E Groopman; Ramesh K Ganju
Journal:  J Addict Dis       Date:  2008

6.  TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications.

Authors:  Jae Young Jang; Seong-Jun Kim; Eun Kyung Cho; Soung Won Jeong; Eui Ju Park; Woong Cheul Lee; Sae Hwan Lee; Sang Gyune Kim; Young Seok Kim; Hong Soo Kim; Boo Sung Kim; Wenyu Lin; Raymond T Chung
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

7.  Association between FAS gene -670 A/G and -1377 G/A polymorphisms and the risk of autoimmune diseases: a meta-analysis.

Authors:  Hongwei Yan; Yuxiao Hong; Yunfei Cai
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.